The Set-Point Study for Type 2 Diabetes: Evaluating the Use of an Insulin Only Bionic Pancreas System in Type 2 Diabetes

NACompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 28, 2017

Primary Completion Date

March 29, 2018

Study Completion Date

March 29, 2018

Conditions
Type 2 Diabetes Mellitus
Interventions
DEVICE

Bionic Pancreas

During this arm the subject will ONLY use our bionic pancreas device with an insulin only configuration using a rapid-acting insulin analog. Subjects will wear a continuous glucose monitoring device (the Dexcom G5) as part of the bionic pancreas, and use the study provided glucose meter.

OTHER

Usual Care

Subject will wear a continuous glucose monitoring device (the Dexcom G5) and use the study provided glucose meter.. Subject will not change their prescribed home insulin therapy regimen during this arm whether that be an insulin pump or multiple daily injections.

Trial Locations (1)

02114

Diabetes Research Center, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT03552523 - The Set-Point Study for Type 2 Diabetes: Evaluating the Use of an Insulin Only Bionic Pancreas System in Type 2 Diabetes | Biotech Hunter | Biotech Hunter